Charles Schwab’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-675,864
| Closed | -$27.2M | – | 3448 |
|
|
2026
Q1 | $27.2M | Buy |
675,864
+31,419
| +5% | +$677K | ﹤0.01% | 1553 |
|
|
2025
Q4 | $16.2M | Sell |
644,445
-2,637
| -0.4% | -$61.9K | ﹤0.01% | 1882 |
|
|
2025
Q3 | $14.6M | Sell |
647,082
-342,061
| -35% | -$7.98M | ﹤0.01% | 1920 |
|
|
2025
Q2 | $17.1M | Buy |
989,143
+24,644
| +3% | +$456K | ﹤0.01% | 1756 |
|
|
2025
Q1 | $21.1M | Sell |
964,499
-32,249
| -3% | -$891K | ﹤0.01% | 1615 |
|
|
2024
Q4 | $31.8M | Buy |
996,748
+40,386
| +4% | +$1.21M | 0.01% | 1423 |
|
|
2024
Q3 | $27.6M | Buy |
956,362
+9,328
| +1% | +$345K | 0.01% | 1517 |
|
|
2024
Q2 | $36.3M | Buy |
947,034
+22,472
| +2% | +$1.02M | 0.01% | 1283 |
|
|
2024
Q1 | $54.3M | Buy |
924,562
+20,153
| +2% | +$1.28M | 0.01% | 985 |
|
|
2023
Q4 | $54.1M | Buy |
904,409
+25,052
| +3% | +$1.27M | 0.01% | 916 |
|
|
2023
Q3 | $33.5M | Buy |
879,357
+50,835
| +6% | +$2.23M | 0.01% | 1163 |
|
|
2023
Q2 | $75.5M | Sell |
828,522
-154,987
| -16% | -$13.4M | 0.02% | 629 |
|
|
2023
Q1 | $64.9M | Buy |
983,509
+582
| +0.1% | +$33.6K | 0.02% | 663 |
|
|
2022
Q4 | $50.8M | Buy |
982,927
+34,168
| +4% | +$1.81M | 0.02% | 800 |
|
|
2022
Q3 | $64.8M | Buy |
948,759
+270,358
| +40% | +$16M | 0.02% | 621 |
|
|
2022
Q2 | $30.7M | Buy |
678,401
+23,093
| +4% | +$1.05M | 0.01% | 1083 |
|
|
2022
Q1 | $33.3M | Buy |
655,308
+63,394
| +11% | +$2.8M | 0.01% | 1155 |
|
|
2021
Q4 | $28M | Buy |
591,914
+73,103
| +14% | +$2.88M | 0.01% | 1315 |
|
|
2021
Q3 | $17.1M | Buy |
518,811
+100,145
| +24% | +$5.63M | 0.01% | 1701 |
|
|
2021
Q2 | $26.5M | Buy |
418,666
+14,539
| +4% | +$750K | 0.01% | 1355 |
|
|
2021
Q1 | $17.3M | Buy |
404,127
+28,628
| +8% | +$1.35M | 0.01% | 1636 |
|
|
2020
Q4 | $21.5M | Buy |
375,499
+6,071
| +2% | +$257K | 0.01% | 1357 |
|
|
2020
Q3 | $11.1M | Buy |
369,428
+7,139
| +2% | +$213K | 0.01% | 1622 |
|
|
2020
Q2 | $11.8M | Buy |
362,289
+31,206
| +9% | +$1M | 0.01% | 1539 |
|
|
2020
Q1 | $8.87M | Buy |
331,083
+61,670
| +23% | +$2.19M | 0.01% | 1514 |
|
|
2019
Q4 | $8.25M | Buy |
269,413
+8,329
| +3% | +$231K | ﹤0.01% | 1751 |
|
|
2019
Q3 | $6.29M | Buy |
261,084
+15,612
| +6% | +$430K | ﹤0.01% | 1857 |
|
|
2019
Q2 | $6.22M | Buy |
245,472
+34,064
| +16% | +$693K | ﹤0.01% | 1869 |
|
|
2019
Q1 | $4.12M | Buy |
211,408
+18,969
| +10% | +$298K | ﹤0.01% | 2067 |
|
|
2018
Q4 | $2.54M | Sell |
192,439
-120
| -0.1% | -$1.84K | ﹤0.01% | 2239 |
|
|
2018
Q3 | $3.42M | Buy |
192,559
+20,380
| +12% | +$377K | ﹤0.01% | 2239 |
|
|
2018
Q2 | $3.79M | Buy |
172,179
+129,488
| +303% | +$2.98M | ﹤0.01% | 2140 |
|
|
2018
Q1 | $944K | Buy |
42,691
+2,949
| +7% | +$58K | ﹤0.01% | 2534 |
|
|
2017
Q4 | $863K | Buy |
+39,742
| New | +$585K | ﹤0.01% | 2556 |
|
Other funds holding APLS
Charles Schwab's APLS Position: Q2 2026 in Review
Charles Schwab sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 675,864 shares — an estimated $27.2M sold.
Charles Schwab first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $75.5M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Charles Schwab reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Charles Schwab sold 675,864 Apellis Pharmaceuticals shares in Q2 2026, an estimated $27.2M.
- Charles Schwab first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
- Charles Schwab's Apellis Pharmaceuticals position peaked at $75.5M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.